| Cysteine cathepsins: from structure, function and regulation to new frontiers V Turk, V Stoka, O Vasiljeva, M Renko, T Sun, B Turk, D Turk Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1824 (1), 68-88, 2012 | 1736 | 2012 |
| Emerging roles of cysteine cathepsins in disease and their potential as drug targets O Vasiljeva, T Reinheckel, C Peters, D Turk, V Turk, B Turk Current pharmaceutical design 13 (4), 387-403, 2007 | 603 | 2007 |
| Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment G Mikhaylov, U Mikac, AA Magaeva, VI Itin, EP Naiden, I Psakhye, ... Nature nanotechnology 6 (9), 594-602, 2011 | 451 | 2011 |
| Tumor cell–derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer O Vasiljeva, A Papazoglou, A Krüger, H Brodoefel, M Korovin, ... Cancer research 66 (10), 5242-5250, 2006 | 444 | 2006 |
| Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index LR Desnoyers, O Vasiljeva, JH Richardson, A Yang, EEM Menendez, ... Science translational medicine 5 (207), 207ra144-207ra144, 2013 | 351 | 2013 |
| Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity J Rozman-Pungerčar, N Kopitar-Jerala, M Bogyo, D Turk, O Vasiljeva, ... Cell Death & Differentiation 10 (8), 881-888, 2003 | 256 | 2003 |
| Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice L Sevenich, U Schurigt, K Sachse, M Gajda, F Werner, S Müller, ... Proceedings of the National Academy of Sciences 107 (6), 2497-2502, 2010 | 200 | 2010 |
| Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion O Vasiljeva, B Turk Biochimie 90 (2), 380-386, 2008 | 152 | 2008 |
| Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans O Vasiljeva, M Dolinar, JR Pungerčar, V Turk, B Turk FEBS letters 579 (5), 1285-1290, 2005 | 148 | 2005 |
| Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice O Vasiljeva, M Korovin, M Gajda, H Brodoefel, L Bojic, A Krüger, ... Oncogene 27 (30), 4191-4199, 2008 | 133 | 2008 |
| Autocatalytic processing of procathepsin B is triggered by proenzyme activity JR Pungerčar, D Caglič, M Sajid, M Dolinar, O Vasiljeva, U Požgan, ... The FEBS journal 276 (3), 660-668, 2009 | 132 | 2009 |
| A role for stefin B (cystatin B) in inflammation and endotoxemia K Maher, BJ Kokelj, M Butinar, G Mikhaylov, M Manček-Keber, V Stoka, ... Journal of biological chemistry 289 (46), 31736-31750, 2014 | 87 | 2014 |
| Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity B Mirković, B Markelc, M Butinar, A Mitrović, I Sosič, S Gobec, O Vasiljeva, ... Oncotarget 6 (22), 19027, 2015 | 78 | 2015 |
| Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor G Mikhaylov, D Klimpel, N Schaschke, U Mikac, M Vizovisek, M Fonovic, ... Angewandte Chemie International Edition 53 (38), 10077-10081, 2014 | 77 | 2014 |
| Cell type-specific functions of the lysosomal protease cathepsin L in the heart D Spira, J Stypmann, DJ Tobin, I Petermann, C Mayer, S Hagemann, ... Journal of Biological Chemistry 282 (51), 37045-37052, 2007 | 73 | 2007 |
| Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof JW West, L Mei, SJ Moore, MTL Nguyen, DR Hostetter, O Vasiljeva, ... US Patent 10,336,824, 2019 | 71 | 2019 |
| Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin L Kramer, M Renko, J Završnik, D Turk, MA Seeger, O Vasiljeva, ... Theranostics 7 (11), 2806, 2017 | 66 | 2017 |
| Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof HB Lowman, LR Desnoyers, S Liu, JW West, JG Sagert, O Vasiljeva, ... US Patent 9,120,853, 2015 | 66 | 2015 |
| Praluzatamab ravtansine, a CD166-targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial V Boni, MJ Fidler, HT Arkenau, A Spira, F Meric-Bernstam, N Uboha, ... Clinical Cancer Research 28 (10), 2020-2029, 2022 | 65 | 2022 |
| Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model M Butinar, MT Prebanda, J Rajković, B Jerič, V Stoka, C Peters, ... Oncogene 33 (26), 3392-3400, 2014 | 60 | 2014 |
Boris TurkProfessor of Biochemistry, Head of Department of Biochemistry and Molecular and Structural BiologyVerified email at ijs.si
